drugset
drugset / Trial / NCT00002965

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

NCT00002965 ↗

Phase 2 Completed 16 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating patients with recurrent unresectable meningiomas and malignant meningiomas.

Timeline

Start
1997-01
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject interferon alfa-2b Protein / enzyme biologic — Subcutaneous

Indications

central nervous system neoplasm